

Übersicht der bestätigten und bewerteten Publikationen

Universitätsklinik und Poliklinik für Gynäkologie Journalbeitrag

Originalarbeit

1. Abera S.F., Kantelhardt E.J., Bezabih A.M., Tsadik M., Lauvai J., Ejeta G., Wienke A., Frank J., Scherbaum V.: (2020) What factors are associated with maternal undernutrition in eastern zone of Tigray, Ethiopia? Evidence for nutritional well-being of lactating mothers. BMC PUBLIC HEALTH, 20: 1214 [32770979](#)
IF: 3,295; anteiliger IF: 0,15684
2. Arians N., Oelmann-Avendano J.T., Schmitt D., Meixner E., Wark A., Hoerner-Rieber J., El Shafie R.A., Lang K., Wallwiener M., Debus J.: (2020) Evaluation of Uterine Brachytherapy as Primary Treatment Option for Elderly Patients with Medically Inoperable Endometrial Cancer-A Single-Center Experience and Review of the Literature. Cancers, 12: 2301 [32824243](#)
IF: 6,639; anteiliger IF: 0,27685
3. Brusniak K., Arndt H.M., Feisst M., Haßdenteufel K., Matthies L.M., Deutsch T.M., Hudalla H., Abele H., Wallwiener M., Wallwiener S.: (2020) Challenges in Acceptance and Compliance in Digital Health Assessments During Pregnancy: Prospective Cohort Study. JMIR mHealth and uHealth, 8: e17377 [33052134](#)
IF: 4,773; anteiliger IF: 0,19903
4. Cardoso F., Paluch-Shimon S., Senkus E., Curigliano G., Aapro M.S., André F., Barrios C.H., Bergh J., Bhattacharyya G.S., Biganzoli L., Boyle F., Cardoso M.J., Carey L.A., Cortés J., El Saghir N.S., Elzayat M., Eniu A., Fallowfield L., Francis P.A., Gelmon K., Gligorov J., Haidinger R., Harbeck N., Hu X., Kaufman B., Kaur R., Kiely B.E., Kim S.B., Lin N.U., Mertz S.A., Neciosup S., Offersen B.V., Ohno S., Pagani O., Prat A., Penault-Llorca F., Rugo H.S., Sledge G.W., Thomssen C., Vorobiof D.A., Wiseman T., Xu B., Norton L., Costa A., Winer E.P.: (2020) 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). ANNALS OF ONCOLOGY, 21: 1623-1649 [32979513](#)
IF: 32,976; anteiliger IF: 0,25721
5. Dereje N., Gebremariam A., Addissie A., Worku A., Assefa M., Abraha A., Tigeneh W., Kantelhardt E.J., Jemal A.: (2020) Factors associated with advanced stage at diagnosis of cervical cancer in Addis Ababa, Ethiopia: a population-based study. BMJ OPEN, 10: e040645 [33051237](#)
IF: 2,692; anteiliger IF: 0,12814
6. Deutsch T.M., Riethdorf S., Fremd C., Feisst M., Nees J., Fischer C., Hartkopf A.D., Pantel K., Trumpp A., Schutz F., Schneeweiss A., Wallwiener M.: (2020) HER2-targeted therapy influences CTC status in metastatic breast cancer. BREAST CANCER RESEARCH AND TREATMENT, 182: 127 [32436146](#)
IF: 4,872; anteiliger IF: 1,62384
7. Deutsch T.M., Stefanovic S., Feisst M., Fischer C., Riedel F., Fremd C., Domschke C., Pantel K., Hartkopf A.D., Sutterlin M., Brucker S.Y., Schneeweiss A., Wallwiener M.: (2020) Cut-Off Analysis of CTC Change under Systemic Therapy for Defining Early Therapy Response in Metastatic Breast Cancer. Cancers, 12: 1055 [32344685](#)
IF: 6,639; anteiliger IF: 2,21278
8. Ditsch N., Untch M., Kolberg-Liedtke C., Jackisch C., Krug D., Friedrich M., Janni W., Müller V., Albert U.S., Banys-Paluchowski M., Bauerfeind I., Blohmer J.U., Budach W., Dall P., Diel I., Fallenberg E.M., Fasching P.A., Fehm T., Gerber B., Gluz O., Hanf V., Harbeck N., Heil J., Huober J., Kreipe H.H., Kühn T., Kümmel S., Loibl S., Lüftner D., Lux M., Maass N., Moebus V., Mundhenke C., Park-Simon T.W., Reimer T., Rhiem K., Rody A., Schmidt M., Schneeweiss A., Solbach C., Solomayer E.F., Stickeler E., Thomssen C., Witzel I., Wöckel A., Thill M.: (2020) AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. BREAST CARE, 15: 294-309 [32774225](#)
IF: 2,86; anteiliger IF: 0,02174
9. Dittmer A., Dittmer J.: (2020) Carcinoma-Associated Fibroblasts Promote Growth of Sox2-Expressing Breast Cancer Cells. Cancers, 12: 3435 [33228022](#)
IF: 6,639; anteiliger IF: 6,639
10. Dittmer A., Lange T., Leyh B., Dittmer J.: (2020) Protein- and growth-modulatory effects of carcinoma-associated fibroblasts on breast cancer cells: Role of interleukin-6. INTERNATIONAL JOURNAL OF ONCOLOGY, 56: 258-272 [31789400](#)
IF: 5,65; anteiliger IF: 5,65038

11. Funk A.Heil J., Harcos A., Gomez C., Stieber A., Junkermann H., Hennigs A., Rauch G., Sinn H.P., Riedel F., Schäfgén B., Hug S., Maier A., Blumenstein M., Domschke C., Schott S., Wallwiener M., Rom J., Schütz F., Sohn C., Golatta M.: (2020) Efficacy of intraoperative specimen radiography as margin assessment tool in breast conserving surgery. BREAST CANCER RESEARCH AND TREATMENT, 179: 425 [31654190](#)
IF: 4,872; anteiliger IF: 0,09013
12. Getachew S., Tesfaw A., Kaba M., Wienke A., Taylor L., Kantelhardt E.J., Addissie A.: (2020) Perceived barriers to early diagnosis of breast Cancer in south and southwestern Ethiopia: a qualitative study. BMC WOMENS HEALTH, 20: 38 [32103774](#)
IF: 2,809; anteiliger IF: 1,1236
13. Gizaw M., Teka B., Ruddies F., Kassahun K., Worku D., Worku A., Wienke A., Mikolajczyk R., Jemal A., Kaufmann A.M., Abebe T., Addissie A., Kantelhardt E.J.: (2020) Reasons for Not Attending Cervical Cancer Screening and Associated Factors in Rural Ethiopia. Cancer Prevention Research, 13: 593-600 [32371553](#)
IF: 3,491; anteiliger IF: 2,43288
14. Goetz M., Schiele C., Müller M., Matthies L.M., Deutsch T.M., Spano C., Graf J., Zipfel S., Bauer A., Brucker S.Y., Wallwiener M., Wallwiener S.: (2020) Effects of a Brief Electronic Mindfulness-Based Intervention on Relieving Prenatal Depression and Anxiety in Hospitalized High-Risk Pregnant Women: Exploratory Pilot Study. JOURNAL OF MEDICAL INTERNET RESEARCH, 22: e17593 [32780023](#)
IF: 5,428; anteiliger IF: 1,80915
15. Hack C.C., Häberle L., Brucker S.Y., Janni W., Volz B., Loehberg C.R., Hartkopf A.D., Walter C.B., Baake G., Fridman A., Malter W., Wuerstlein R., Harbeck N., Hoffmann O., Kuemmel S., Martin B., Thomssen C., Graf H., Wolf C., Lux M.P., Bayer C.M., Rauh C., Almstedt K., Gass P., Heindl F., Brodkorb T., Willer L., Lindner C., Kolberg H.C., Krabisch P., Weigel M., Steinfeld-Birg D., Kohls A., Brucker C., Schulz V., Fischer G., Pelzer V., Rack B., Beckmann M.W., Fehm T., Rody A., Maass N., Hein A., Fasching P.A., Nabieva N.: (2020) Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients. BREAST, 50: 11-18 [31958661](#)
IF: 4,38; anteiliger IF: 0,03395
16. Hartkopf A.D., Emons J., Lux M.P., Taran F.A., Overkamp F., Tesch H., Titzmann A., Poschke P., Lüftner D., Wallwiener M., Müller V., Beckmann M.W., Belleville E., Janni W., Fehm T., Kolberg H.C., Ettl J., Wallwiener D., Schneeweiss A., Brucker S.Y., Fasching P.: (2020) Clinical endpoints in real-world registry studies PRAEGNANT network for women with advanced breast cancer. ONKOLOGE, 26: 530-541
IF: 0,234; anteiliger IF: 0,0041
17. Haßdenteufel K., Feißt M., Brusniak K., Lingenfelder K., Matthies L.M., Wallwiener M., Wallwiener S.: (2020) Reduction in physical activity significantly increases depression and anxiety in the perinatal period: a longitudinal study based on a self-report digital assessment tool. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 302: 53 [32372342](#)
IF: 2,344; anteiliger IF: 0,15634
18. Huebner H., Kurbacher C.M., Kuesters G., Hartkopf A.D., Lux M.P., Huober J., Volz B., Taran F.A., Overkamp F., Tesch H., Häberle L., Lüftner D., Wallwiener M., Müller V., Beckmann M.W., Belleville E., Ruebner M., Untch M., Fasching P.A., Janni W., Fehm T.N., Kolberg H.C., Wallwiener D., Brucker S.Y., Schneeweiss A., Ettl J.: (2020) Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. BMC CANCER, 20: 1091 [33176725](#)
IF: 4,43; anteiliger IF: 0,06158
19. Joko-Fru W.Y., Miranda-Filho A., Soerjomataram I., Egue M., Akele-Akpo M.T., N'da G., Assefa M., Buziba N., Korir A., Kamate B., Traore C., Manraj S., Lorenzoni C., Carrilho C., Hansen R., Finesse A., Somdyala N., Wabinga H., Chingonzoh T., Borok M., Chokunonga E., Liu B., Kantelhardt E., McGale P., Parkin D.M.: (2020) Breast cancer survival in sub-Saharan Africa by age, stage at diagnosis and human development index: A population-based registry study. INTERNATIONAL JOURNAL OF CANCER, 146: 1208-1218 [31087650](#)
IF: 7,396; anteiliger IF: 0,10724
20. Kantelhardt E.J., Assefa M., McCormack V., Cubasch H., Jemal A., Pace L.E.: (2020) Expert Discussion: Breast Cancer in Low-Resource Countries. BREAST CARE, 15: 310-313 [32774226](#)
IF: 2,86; anteiliger IF: 0,95324
21. Kroeber E.S., Adam L., Addissie A., Bauer A., Frese T., Kantelhardt E.J., Unverzagt S.: (2020) Protocol for a systematic review on tertiary prevention interventions for patients with stroke in African countries. BMJ OPEN, 10: e038459 [32928859](#)
IF: 2,692; anteiliger IF: 0,17956

22. Laakmann E., Emons J., Taran F.A., Janni W., Uhrig S., Overkamp F., Kolberg H.C., Hadji P., Tesch H., Häberle L., Ettl J., Lüftner D., Wallwiener M., Schulmeyer C., Müller V., Beckmann M.W., Belleville E., Wimberger P., Hielscher C., Kurbacher C., Wuerstlein R., Thomssen C., Untch M., Volz B., Fasching P.A., Fehm T.N., Wallwiener D., Brucker S.Y., Schneeweiss A., Hartkopf A.D.: (2020) Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine. GEBURTSHILFE UND FRAUENHEILKUNDE, 80: 1134 [33173241](#)
IF: 2,915; anteiliger IF: 0,06939
23. Matthies L.M., Müller M., Doster A., Sohn C., Wallwiener M., Reck S., Wallwiener S.: (2020) Maternal-fetal attachment protects against postpartum anxiety: the mediating role of postpartum bonding and partnership satisfaction. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 301: 107 [31875254](#)
IF: 2,344; anteiliger IF: 0,15634
24. Mezger N.C.S., Feuchtner J., Griesel M., Hämmerl L., Seraphin T.P., Zietsman A., Péko J.F., Tadesse F., Buziba N.G., Wabinga H., Nyanchama M., Borok M.Z., Kéita M., N'da G., Lorenzoni C.F., Akele-Akpo M.T., Gottschick C., Binder M., Mezger J., Jemal A., Parkin D.M., Wickenhauser C., Kantelhardt E.J.: (2020) Clinical presentation and diagnosis of adult patients with non-Hodgkin lymphoma in Sub-Saharan Africa. BRITISH JOURNAL OF HAEMATOLOGY, 190: 209-221 [32181503](#)
IF: 6,998; anteiliger IF: 5,10994
25. Michel L.L., Hartkopf A.D., Fasching P.A., Kolberg H.C., Hadji P., Tesch H., Häberle L., Ettl J., Lüftner D., Wallwiener M., Müller V., Beckmann M.W., Belleville E., Volz B., Huebner H., Wimberger P., Hielscher C., Mundhenke C., Kurbacher C., Wuerstlein R., Untch M., Overkamp F., Huober J., Janni W., Taran F.A., Lux M.P., Wallwiener D., Brucker S.Y., Schneeweiss A., Fehm T.N.: (2020) Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. Cancers, 12: 3021 [33080911](#)
IF: 6,639; anteiliger IF: 0,079
26. Mokry T., Mlynarska-Bujny A., Kuder T.A., Hasse F.C., Hog R., Wallwiener M., Dinkic C., Brucker J., Sinn P., Gnirs R., Kauczor H.U., Schlemmer H.P., Rom J., Bickelhaupt S.: (2020) Ultra-High-b-Value Kurtosis Imaging for Noninvasive Tissue Characterization of Ovarian Lesions. RADIOLOGY, 296: 358-369
IF: 11,105; anteiliger IF: 0,30872
27. Müller M., Matthies L.M., Goetz M., Abele H., Brucker S.Y., Bauer A., Graf J., Zipfel S., Hasemann L., Wallwiener M., Wallwiener S.: (2020) Effectiveness and cost-effectiveness of an electronic mindfulness-based intervention (eMBI) on maternal mental health during pregnancy: the mindmom study protocol for a randomized controlled clinical trial. TRIALS, 21: 933 [33203471](#)
IF: 2,279; anteiliger IF: 0,08432
28. Ortmann O., Torode J., Schmiegel W., Thomssen C., Hakama M., Basu P., Ringborg U., Helbig U., participants of the ERTM: (2020) Knowledge transfer as a tool towards improvement of cancer care in low- and middle-income countries. 6th European Roundtable Meeting (ERTM), June 14th, 2019, Berlin, Germany. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 146: 1813-1818 [32270287](#)
IF: 4,553; anteiliger IF: 0,30369
29. Parkin D.M., Hämmerl L., Ferlay J., Kantelhardt E.J.: (2020) Cancer in Africa 2018: The role of infections. INTERNATIONAL JOURNAL OF CANCER, 146: 2089-2103 [31254479](#)
IF: 7,396; anteiliger IF: 3,698
30. Riedel F., Hoffmann A.S., Moderow M., Heublein S., Deutsch T., Golatta M., Wallwiener M., Schneeweiss A., Heil J., Hennigs A.: (2020) Time trends of neoadjuvant chemotherapy for early breast cancer. INTERNATIONAL JOURNAL OF CANCER, 147: 3049 [32468577](#)
IF: 7,396; anteiliger IF: 0,30841
31. Ruddies F., Gizaw M., Teka B., Thies S., Wienke A., Kaufmann A.M., Abebe T., Addissie A., Kantelhardt E.J.: (2020) Cervical cancer screening in rural Ethiopia: a cross-sectional knowledge, attitude and practice study. BMC CANCER, 20: 563 [32552740](#)
IF: 4,43; anteiliger IF: 3,16391
32. Schmid P., Cortes J., Pusztai L., McArthur H., Kümmel S., Bergh J., Denkert C., Park Y.H., Hui R., Harbeck N., Takahashi M., Foukakis T., Fasching P.A., Cardoso F., Untch M., Jia L., Karantza V., Zhao J., Aktan G., Dent R., O'Shaughnessy J., KEYNOTE-522 Investigators: (2020) Pembrolizumab for Early Triple-Negative Breast Cancer. NEW ENGLAND JOURNAL OF MEDICINE, 382: 810-821 [32101663](#)
IF: 91,245; anteiliger IF: 0,42885
33. Schneeweiss A., Bauerfeind I., Fehm T., Janni W., Thomssen C., Witzel I., Wöckel A., Müller V.: (2020)

Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer.

BREAST CARE, 15: 608-618 [33447235](#)

IF: 2,86; anteiliger IF: 0,15889

34. Schneeweiss A., Ettl J., Lüftner D., Beckmann M.W., Belleville E., Fasching P.A., Fehm T.N., Geberth M., Häberle L., Hadji P., Hartkopf A.D., Hielscher C., Huober J., Ruckhäberle E., Janni W., Kolberg H.C., Kurbacher C.M., Klein E., Lux M.P., Müller V., Nabieva N., Overkamp F., Tesch H., Laakmann E., Taran F.A., Seitz J., Thomssen C., Untch M., Wimberger P., Wuerstlein R., Volz B., Wallwiener D., Wallwiener M., Brucker S.Y.: (2020) Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. BREAST, 54: 88 [32956934](#)
IF: 4,38; anteiliger IF: 0,0911
35. Seliger G., Krol I., Worlitzsch D., Kantelhardt E.J., Moritz S., Tchirikov M.: (2020) [Reduction of Visitor- and Staff-Associated Risk of Infection by Complex Intervention in the Department of Feto-Maternal Medicine]. ZEITSCHRIFT FUR GEBURTSHILFE UND NEONATOLOGIE, 224: 297-305 [32906163](#)
IF: 0,685; anteiliger IF: 0,05706
36. Sengayi-Muchengeti M., Joko-Fru W.Y., Miranda-Filho A., Egue M., Akele-Akpo M.T., N'da G., Mathewos A., Buziba N., Korir A., Manraj S., Lorenzoni C., Carrilho C., Hansen R., Finesse A., Somdyala N.I.M., Wabinga H., Chingonzoh T., Borok M., Chokunonga E., Liu B., Singh E., Kantelhardt E.J., Parkin D.M.: (2020) Cervical cancer survival in sub-Saharan Africa by age, stage at diagnosis and Human Development Index: A population-based registry study. INTERNATIONAL JOURNAL OF CANCER, 147: 3037-3048 [32449157](#)
IF: 7,396; anteiliger IF: 0,1176
37. Steanovic S., Deutsch T.M., Wirtz R., Hartkopf A., Sinn P., Ohler M., Hofmann J., Bankovic S., Vassilev K., Sutterlin M., Schneeweiss A., Wallwiener M.: (2020) Impact of mRNA-Assessed Molecular Subtype Conversion, Intact and Apoptotic Circulating Tumor Cells on Survival of Metastatic Breast Cancer Patients: Proof of Principle. Diagnostics, 10: Epub [32512707](#)
IF: 3,706; anteiliger IF: 1,23521
38. Stefanovic S., Deutsch T.M., Riethdorf S., Fischer C., Hartkopf A., Sinn P., Feisst M., Pantel K., Golatta M., Brucker S.Y., Sütterlin M., Schneeweiss A., Wallwiener M.: (2020) The Lack of Evidence for an Association between Cancer Biomarker Conversion Patterns and CTC-Status in Patients with Metastatic Breast Cancer. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 21: 2161 [32245182](#)
IF: 5,923; anteiliger IF: 1,97414
39. Swain S.M., Miles D., Kim S.B., Im Y.H., Im S.A., Semiglazov V., Ciruelos E., Schneeweiss A., Loi S., Monturus E., Clark E., Knott A., Restuccia E., Benyunes M.C., Cortés J., CLEOPATRA study group: (2020) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. LANCET ONCOLOGY, 21: 519-530 [32171426](#)
IF: 41,316; anteiliger IF: 0,20245
40. Thomssen C., Lüftner D., Untch M., Haidinger R., Würstlein R., Harbeck N., Augustin D., Briest S., Ettl J., Fasching P.A., Förster F., Kurbacher C.M., Lück H.J., Marschner N., Müller L., Müller V., Perlova-Griff L., Radke I., Ruckhäberle E., Scheffen I., Schumacher-Wulf E., Schwoerer M., Steinfeld-Birg D., Ziegler-Löhr K.: (2020) International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of Experts. BREAST CARE, 15: 82-95 [32231503](#)
IF: 2,86; anteiliger IF: 0,95324
41. Torres-de la Roche L.A., Wallwiener M., De Wilde R.L.: (2020) Obstetrical outcome in the third trimester after hysteroscopic adhesiolysis. Annals of Translational Medicine, 8: 664 [32617284](#)
IF: 3,932; anteiliger IF: 1,31054
42. Untch M., Würstlein R., Lüftner D., Haidinger R., Fasching P.A., Augustin D., Briest S., Ettl J., Förster F., Kurbacher C.M., Lück H.J., Marschner N., Müller L., Müller V., Radke I., Ruckhäberle E., Scheffen I., Schumacher-Wulf E., Schwoerer M., Steinfeld-Birg D., Ziegler-Löhr K., Thomssen C., Harbeck N.: (2020) ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019: Commentary by the German panel of experts on the ABC5 voting results. GEBURTSHILFE UND FRAUENHEILKUNDE, 80: 588-600 [32565549](#)
IF: 2,915; anteiliger IF: 0,04635
43. Walter V., Fischer C., Deutsch T.M., Ersing C., Nees J., Schütz F., Fremd C., Grischke E.M., Sinn P., Brucker S.Y., Schneeweiss A., Hartkopf A.D., Wallwiener M.: (2020) Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer. BREAST CANCER

RESEARCH AND TREATMENT, 183: 137 [32613540](#)
IF: 4,872; anteiliger IF: 1,62384

44. Walter V.P., Taran F.A., [Wallwiener M.](#), Bauer A., Grischke E.M., Walter C.B., Hahn M., Brucker S.Y., Hartkopf A.D.: (2020) Distribution of the 21-Gene Breast Recurrence Score in Patients with Primary Breast Cancer in Germany. GEBURTSHILFE UND FRAUENHEILKUNDE, 80: 619 [32565552](#)
IF: 2,915; anteiliger IF: 0,13875
45. [Wondimagegnehu A.](#), Hirpa S., Abaya S.W., [Gizaw M.](#), [Getachew S.](#), [Ayele W.](#), Yirgu R., Demeke T., Dessalegn B., Diribi J., Kaba M., Assefa M., Jemal A., [Kantelhardt E.J.](#), Addissie A.: (2020) Oesophageal cancer magnitude and presentation in Ethiopia 2012-2017. PLoS One, 15: e0242807 [33259514](#)
IF: 3,24; anteiliger IF: 1,41167
46. [Ziegenhorn H.V.](#), Frie K.G., Ekanem I.O., Ebughe G., Kamate B., Traore C., Dzamalala C., Ogunbiyi O., Igbinoba F., Liu B., Bauer M., [Thomssen C.](#), Parkin D.M., Wickenhauser C., [Kantelhardt E.J.](#): (2020) Breast cancer pathology services in sub-Saharan Africa: a survey within population-based cancer registries. BMC HEALTH SERVICES RESEARCH, 20: 912 [33008380](#)
IF: 2,655; anteiliger IF: 1,83779

2020 Summe der Bewertungen: 48,98677, Summe IF = 354.93

Originalarbeit

1. Abebe L.G., [Wondimagegnehu A.](#), Woldemariam A.A., Gelaye B., [Kantelhardt E.J.](#), [Addissie A.](#): (2021) Validity and Reliability of the Amharic Version of EORTC-QLQ-CR29 Among Colorectal Cancer Patients in Ethiopia. Cancer Management and Research, 13: 9287-9295 [34992454](#)
IF: 3,602; anteiliger IF: 1,80076
2. Abera S.F., Mikolajczyk R.T., [Kantelhardt E.J.](#), Efremov L., Bedir A., Ostheimer C., Glowka A., Vordermark D., Medenwald D.: (2021) Lung Cancer Attributed Mortality Among 316,336 Early Stage Breast Cancer Cases Treated by Radiotherapy and/or Chemotherapy, 2000-2015: Evidence From the SEER Database. Frontiers in Oncology, 10: 602397 [33718108](#)
IF: 5,738; anteiliger IF: 0,27313
3. Afework T., [Wondimagegnehu A.](#), Alemayehu N., [Kantelhardt E.J.](#), [Addissie A.](#): (2021) Validity and reliability of the Amharic version of supportive care needs survey - short form 34 among cancer patients in Ethiopia. BMC HEALTH SERVICES RESEARCH, 21: 484 [34020635](#)
IF: 2,908; anteiliger IF: 1,29235
4. [Ayele W.](#), Addissie A., Wienke A., Unverzagt S., Jemal A., Taylor L., [Kantelhardt E.J.](#): (2021) Breast Awareness, Self-Reported Abnormalities, and Breast Cancer in Rural Ethiopia: A Survey of 7,573 Women and Predictions of the National Burden. ONCOLOGIST, 26: e1009 [33650727](#)
IF: 5,837; anteiliger IF: 3,89114
5. Berdiel-Acer M., Maia A., Hristova Z., Borgoni S., [Vetter M.](#), Burmester S., Becki C., Michels B., Abnaof K., Binenbaum I., Bethmann D., Chatziioannou A., Hasmann M., [Thomssen C.](#), Espinet E., Wiemann S.: (2021) Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts. ONCOGENE, 40: 2651-2666 [33692466](#)
IF: 8,756; anteiliger IF: 0,41687
6. Bley N., Schott A., Müller S., Misiak D., Lederer M., Fuchs T., Aßmann C., Glaß M., Ihling C., Sinz A., Pazaitis N., Wickenhauser C., [Vetter M.](#), Ungurs O., [Strauss H.G.](#), [Thomssen C.](#), Hüttelmaier S.: (2021) IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer. RNA Biology, 18: 391 [32876513](#)
IF: 4,766; anteiliger IF: 0,31742
7. COVIDSurg Collaborative, GlobalSurg Collaborative, Kisser U., Kleeff J., Klose J., Lorenz K., [Papendick N.](#), Plontke S., Ronellenfisch U., Seiwert I., Steer S., [Thomssen C.](#), Ukkat J., Scherl C.: (2021) SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study. BRITISH JOURNAL OF SURGERY, 108: 1056 [33761533](#)
IF: 11,122; anteiliger IF: 0,00222
8. COVIDSurg Collaborative, GlobalSurg Collaborative, Kisser U., Kleeff J., Klose J., Lorenz K., [Papendick N.](#), Plontke S., Ronellenfisch U., Seiwert I., [Thomssen C.](#), Ukkat J., Scherl C.: (2021) Effects of pre-operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort

study. ANAESTHESIA, 76: 1454-1464 [34371522](#)

IF: 12,893; anteiliger IF: 0,00258

9. COVIDSurg Collaborative, GlobalSurg Collaborative, Kissler U., Ronellenfisch U., Kleeff J., Ukkat J., Klose J., Lorenz K., [Papendick N.](#), Plontke S., Seiwerth I., [Thomssen C.](#), Scherl C.: (2021) Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study. ANAESTHESIA, 76: 748 [33690889](#)
IF: 12,893; anteiliger IF: 0,00258
10. Dereje N., Addissie A., Worku A., Gebremariam A., [Kantelhardt E.J.](#), Assefa M., Jemal A.: (2021) Association between waiting time for radiotherapy initiation and disease progression among women with cervical cancer in Addis Ababa, Ethiopia. INTERNATIONAL JOURNAL OF CANCER, 149: 1284-1289 [33997978](#)
IF: 7,316; anteiliger IF: 0,48773
11. Deressa B.T., Assefa M., Tafesse E., [Kantelhardt E.J.](#), Soldatovic I., Cihoric N., Rauch D., Jemal A.: (2021) Contemporary treatment patterns and survival of cervical cancer patients in Ethiopia. BMC CANCER, 21: 1102 [34645407](#)
IF: 4,638; anteiliger IF: 0,25767
12. Desalegn Z., Deyessa N., Teka B., Shiferaw W., Hailemariam D., Addissie A., Abagero A., Kaba M., Abebe W., Nega B., Ayele W., Haile T., Gebrehiwot Y., Amogne W., [Kantelhardt E.J.](#), Abebe T.: (2021) COVID-19 and the public response: Knowledge, attitude and practice of the public in mitigating the pandemic in Addis Ababa, Ethiopia. PLoS One, 16: e0244780 [33411766](#)
IF: 3,752; anteiliger IF: 0,0893
13. Desalegn Z., Deyessa N., Teka B., Shiferaw W., Yohannes M., Hailemariam D., Addissie A., Abagero A., Kaba M., Abebe W., Abrha A., Nega B., Ayele W., Haile T., Gebrehiwot Y., Amogne W., [Kantelhardt E.J.](#), Abebe T.: (2021) Evaluation of COVID-19 related knowledge and preparedness in health professionals at selected health facilities in a resource-limited setting in Addis Ababa, Ethiopia. PLoS One, 16: e0244050 [33566814](#)
IF: 3,752; anteiliger IF: 0,07817
14. Destaw A., Midaksa M., Addissie A., [Kantelhardt E.J.](#), Gizaw M.: (2021) Cervical cancer screening "see and treat approach": real-life uptake after invitation and associated factors at health facilities in Gondar, Northwest Ethiopia. BMC CANCER, 21: 1031 [34530761](#)
IF: 4,638; anteiliger IF: 2,06118
15. Ditsch N., Kolberg-Liedtke C., Friedrich M., Jackisch C., Albert U.S., Banys-Paluchowski M., Bauerfeind I., Blohmer J.U., Budach W., Dall P., Fallenberg E.M., Fasching P.A., Fehm T., Gerber B., Gluz O., Harbeck N., Heil J., Hooper J., Kreipe H.H., Krug D., Kühn T., Kümmel S., Loibl S., Lüftner D., Lux M.P., Maass N., Mundhenke C., Nitz U., Park-Simon T.W., Reimer T., Rhiem K., Rody A., Schmidt M., Schneeweiss A., Schütz F., Sinn H.P., Solbach C., Solomayer E.F., Stickeler E., [Thomssen C.](#), Untch M., Witzel I., Wöckel A., Müller V., Janni W., Thill M.: (2021) AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. BREAST CARE, 16: 214-227 [34248462](#)
IF: 2,268; anteiliger IF: 0,01718
16. Ditsch N., Stickeler E., Behrens A., Belleville E., Fasching P.A., Fehm T.N., Hartkopf A.D., Jackisch C., Janni W., Kolberg-Liedtke C., Kolberg H.C., Lüftner D., Lux M.P., Müller V., Schneeweiss A., Schütz F., Schulmeyer C.E., Tesch H., [Thomssen C.](#), Uleer C., Untch M., Welslau M., Wöckel A., Wurmthaler L.A., Würstlein R., Thill M., Aktas B.: (2021) Update Breast Cancer 2021 Part 2 - Advanced Stages, Long-Term Consequences and Biomarkers. GEBURTSHILFE UND FRAUENHEILKUNDE, 81: 539-548 [34035548](#)
IF: 2,754; anteiliger IF: 0,03672
17. Dittmer J.: (2021) Nuclear Mechanisms Involved in Endocrine Resistance. Frontiers in Oncology, 11: 736597 [34604071](#)
IF: 5,738; anteiliger IF: 5,738
18. Dominguez-Valentin M., Crosbie E.J., Engel C., Aretz S., Macrae F., Winship I., Capella G., Thomas H., Nakken S., Hovig E., Nielsen M., Sijmons R.H., Bertario L., Bonanni B., Tibiletti M.G., Cavestro G.M., Mints M., Gluck N., Katz L., Heinemann K., Vaccaro C.A., Green K., Laloo F., Hill J., Schmiegel W., Vangala D., Perne C., [Strauß H.G.](#), Tecklenburg J., Holinski-Feder E., Steinke-Lange V., Mecklin J.P., Plazzer J.P., Pineda M., Navarro M., Vidal J.B., Kariv R., Rosner G., Piñero T.A., Gonzalez M.L., Kalfayan P., Ryan N., Ten Broeke S.W., Jenkins M.A., Sunde L., Bernstein I., Burn J., Greenblatt M., de Vos Tot Nederveen Cappel W.H., Della Valle A., Lopez-Koestner F., Alvarez K., Büttner R., Görgens H., Morak M., Holzapfel S., Hüneburg R., von Knebel Doeberitz M., Loeffler M., Rahner N., Weitz J., Pylvänäinen K., Renkonen-Sinisalo L., Lepistö A., Auranen A., Hopper J.L., Win A.K., Haile R.W., Lindor N.M., Gallinger S., Le Marchand L., Newcomb P.A., Figueiredo J.C., Thibodeau S.N., Therkildsen C., Okkels H., Ketabi Z., Denton O.G., Rødland E.A., Vasen H., Neffa F., Esperon P., Tjandra D., Möslin G., Sampson J.R., Evans D.G., Seppälä T.T., Møller P.: (2021) Risk-reducing

hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. GENETICS IN MEDICINE, 23: 705-712 [33257847](#)
IF: 8,864; anteiliger IF: 0,03436

19. Fasching P.A., Yadav S., Hu C., Wunderle M., Häberle L., Hart S.N., Rübner M., Polley E.C., Lee K.Y., Gnanaolivu R.D., Hadji P., Hübner H., Tesch H., Ettl J., Overkamp F., Lux M.P., Ekici A.B., Volz B., Uhrig S., Lüftner D., Wallwiener M., Müller V., Belleville E., Untch M., Kolberg H.C., Beckmann M.W., Reis A., Hartmann A., Janni W., Wimberger P., Taran F.A., Fehm T.N., Wallwiener D., Brucker S.Y., Schneeweiss A., Hartkopf A.D., Couch F.J.: (2021) Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis. Journal of clinical oncology, 39: 1619 [33780288](#)
IF: 50,717; anteiliger IF: 0,48181
20. Fehm T.N., Stickeler E., Fasching P.A., Janni W., Kolberg-Liedtke C., Kolberg H.C., Lüftner D., Müller V., Schütz F., Thomssen C., Belleville E., Behrens A., Bader S., Untch M., Welslau M., Würstlein R., Thill M., Krug D., Hartkopf A.D.: (2021) Update Breast Cancer 2021 Part 3 - Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel. GEBURTSHILFE UND FRAUENHEILKUNDE, 81: 654-665 [34168379](#)
IF: 2,754; anteiliger IF: 0,054
21. Friedrich M., Kühn T., Janni W., Müller V., Banyas-Pachulowski M., Kolberg-Liedtke C., Jackisch C., Krug D., Albert U.S., Bauerfeind I., Blohmer J., Budach W., Dall P., Fallenberg E.M., Fasching P.A., Fehm T., Gerber B., Gluz O., Hanf V., Harbeck N., Heil J., Huober J., Kreipe H.H., Kümmel S., Loibl S., Lüftner D., Lux M.P., Maass N., Möbus V., Mundhenke C., Nitz U., Park-Simon T.W., Reimer T., Rhiem K., Rody A., Schmidt M., Schneeweiss A., Schütz F., Sinn H.P., Solbach C., Solomayer E.F., Stickeler E., Thomssen C., Untch M., Witzel I., Wöckel A., Thill M., Ditsch N.: (2021) AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update. GEBURTSHILFE UND FRAUENHEILKUNDE, 81: 1112-1120 [34629490](#)
IF: 2,754; anteiliger IF: 0,01996
22. Gayatri D., Efremov L., Kantelhardt E.J., Mikolajczyk R.: (2021) Quality of life of cancer patients at palliative care units in developing countries: systematic review of the published literature. QUALITY OF LIFE RESEARCH, 30: 315-343 [32948975](#)
IF: 3,44; anteiliger IF: 0,57345
23. Gayatri D., Efremov L., Mikolajczyk R., Kantelhardt E.J.: (2021) Quality of Life Assessment and Pain Severity in Breast Cancer Patients Prior to Palliative Oncology Treatment in Indonesia: A Cross-Sectional Study. Patient Preference and Adherence, 15: 2017-2026 [34548783](#)
IF: 2,314; anteiliger IF: 0,77133
24. Gebremariam A., Assefa M., Addissie A., Worku A., Dereje N., Abreha A., Tigeneh W., Pace L.E., Kantelhardt E.J., Jemal A.: (2021) Delayed initiation of adjuvant chemotherapy among women with breast cancer in Addis Ababa, Ethiopia. BREAST CANCER RESEARCH AND TREATMENT, 187: 877-882 [33599864](#)
IF: 4,624; anteiliger IF: 0,19267
25. Gebremariam A., Dereje N., Addissie A., Worku A., Assefa M., Abreha A., Tigeneh W., Pace L.E., Kantelhardt E.J., Jemal A.: (2021) Factors associated with late-stage diagnosis of breast cancer among women in Addis Ababa, Ethiopia. BREAST CANCER RESEARCH AND TREATMENT, 185: 117-124 [32948993](#)
IF: 4,624; anteiliger IF: 0,19282
26. Griesel M., Seraphin T.P., Mezger N.C., Hämmerl L., Feuchtner J., Joko-Fru W.Y., Sengayi-Muchengeti M., Liu B., Vuma S., Korir A., Chesumbai G.C., Nambooze S., Lorenzoni C.F., Akele-Akpo M.T., Ayemou A., Traoré C.B., Wondemagegnehu T., Wienke A., Thomssen C., Parkin D.M., Jemal A., Kantelhardt E.J.: (2021) Cervical Cancer in Sub-Saharan Africa: A Multinational Population-Based Cohort Study of Care and Guideline Adherence. ONCOLOGIST, 26: e807-e816 [33565668](#)
IF: 5,837; anteiliger IF: 4,37833
27. Grimm D., Voiss P., Paepke D., Dietmaier J., Cramer H., Kümmel S., Beckmann M.W., Woelber L., Schmalfeldt B., Freitag U., Kalder M., Wallwiener M., Theuser A.K., Hack C.C.: (2021) Gynecologists' attitudes toward and use of complementary and integrative medicine approaches: results of a national survey in Germany. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 303: 967 [33201377](#)
IF: 2,493; anteiliger IF: 0,06931
28. Gullickson C., Goodman M., Joko-Fru Y.W., Gnanngnon F.H.R., N'Da G., Woldegeorgis M.A., Buziba N.G., Karugu C., Manraj S.S., Lorenzoni C.F., Hansen R., Finesse A., Somdyala N.I.M., Bukirwa P., Chingonzoh T., Chokunonga E., Liu B., Kantelhardt E., Parkin D.M., Jemal A.: (2021) Colorectal cancer survival in sub-

Saharan Africa by age, stage at diagnosis and Human Development Index: A population-based registry study. INTERNATIONAL JOURNAL OF CANCER, 149: 1553-1563 [34164808](#)
IF: 7,316; anteiliger IF: 0,13535

29. Hartkopf A.D., Brucker S.Y., Taran F.A., Harbeck N., von Au A., Naume B., Pierga J.Y., Hoffmann O., Beckmann M.W., Rydén L., Fehm T., Aft R., Solà M., Walter V., Rack B., Schuetz F., Borgen E., Ta M.H., Bittner A.K., Fasching P.A., Fernö M., Krawczyk N., Weilbaecher K., Margeli M., Hahn M., Jueckstock J., Domschke C., Bidard F.C., Kasimir-Bauer S., Schoenfish B., Kurt A.G., Wallwiener M., Gebauer G., Klein C.A., Wallwiener D., Janni W., Pantel K.: (2021) Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. EUROPEAN JOURNAL OF CANCER, 154: 128 [34265505](#)
IF: 10,002; anteiliger IF: 0,09502
30. Hartung C., Porsch M., Stückerath K., Kaufhold S., Staeger M.S., Hanf V., Lantzsch T., Uleer C., Peschel S., John J., Pöhler M., Weigert E., Buchmann J., Bürrig K.F., Schüler K., Bethmann D., Große I., Kantelhardt E.J., Thomssen C., Vetter M.: (2021) Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping. BREAST CARE, 16: 637 [35082572](#)
IF: 2,268; anteiliger IF: 1,72176
31. Haßdenteufel K., Lingenfelder K., Schwarze C.E., Feisst M., Brusniak K., Matthies L.M., Goetz M., Wallwiener M., Wallwiener S.: (2021) Evaluation of Repeated Web-Based Screening for Predicting Postpartum Depression: Prospective Cohort Study. JMIR Mental Health, 8: e26665 [34890349](#)
IF: 6,332; anteiliger IF: 0,3014
32. Hein A., Hartkopf A.D., Emons J., Lux M.P., Volz B., Taran F.A., Overkamp F., Hadji P., Tesch H., Häberle L., Ettl J., Lüftner D., Wurmthaler L.A., Wallwiener M., Müller V., Beckmann M.W., Belleville E., Wimberger P., Hielscher C., Kurbacher C.M., Wuerstlein R., Thomssen C., Untch M., Fasching P.A., Janni W., Fehm T.N., Wallwiener D., Brucker S.Y., Schneeweiss A., Kolberg H.C.: (2021) Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. EUROPEAN JOURNAL OF CANCER, 155: 1 [34311211](#)
IF: 10,002; anteiliger IF: 0,11902
33. Hirpa S., Fogarty A., Addissie A., Bauld L., Frese T., Unverzagt S., Kantelhardt E.J., Getachew S., Deressa W.: (2021) An Emerging Problem of Shisha Smoking among High School Students in Ethiopia. International Journal of Environmental Research and Public Health, 18: 1 [34209200](#)
IF: 4,614; anteiliger IF: 0,43934
34. Joko-Fru W.Y., Griesel M., Mezger N.C.S., Hämmerl L., Seraphin T.P., Feuchtner J., Wabinga H., N'da G., Mathewos A., Kamaté B., Nsonde Malanda J., Gnangnon F.H.R., Chesumbai G.C., Korir A., Lorenzoni C., Zietsman A., Borok M.Z., Liu B., Thomssen C., McGale P., Jemal A., Parkin D.M., Kantelhardt E.J.: (2021) Breast Cancer Diagnostics, Therapy, and Outcomes in Sub-Saharan Africa: A Population-Based Registry Study. Journal of the National Comprehensive Cancer Network, XXX-XXX: 1-11 [34965508](#)
IF: 12,693; anteiliger IF: 5,44157
35. Krajnak S., Decker T., Schollenberger L., Rosé C., Ruckes C., Fehm T., Thomssen C., Harbeck N., Schmidt M.: (2021) Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy: VinoMetro-AGO-B-046. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 147: 3391-3400 [33743073](#)
IF: 4,322; anteiliger IF: 0,20581
36. Lier E.J., van den Beukel B.A.W., Gawria L., van der Wees P.J., van den Hil L., Bouvy N.D., Cheong Y., de Wilde R.L., CLAS, van goor H., Stommel M.W.J., Ten Broek R.P.G.: (2021) Clinical adherence score (CLAS): development of a novel clinical score for adherence-related complications in abdominal and pelvic surgery. SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 35: 2159 [32410083](#)
IF: 3,453; anteiliger IF: 0,07838
37. Lüftner D., Hartkopf A.D., Lux M.P., Overkamp F., Tesch H., Titzmann A., Pöschke P., Wallwiener M., Müller V., Beckmann M.W., Belleville E., Janni W., Fehm T.N., Kolberg H.C., Ettl J., Wallwiener D., Schneeweiss A., Brucker S.Y., Fasching P.A.: (2021) Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer. BREAST CARE, 16: 108 [34007260](#)
IF: 2,268; anteiliger IF: 0,04445
38. Lux M.P., Schneeweiss A., Hartkopf A.D., Müller V., Janni W., Belleville E., Stickeler E., Thill M., Fasching P.A., Kolberg H.C., Untch M., Harbeck N., Wöckel A., Thomssen C., Schulmeyer C.E., Welslau M., Overkamp F., Schütz F., Lüftner D., Ditsch N.: (2021) Update Breast Cancer 2020 Part 5 - Moving Therapies From Advanced to Early Breast Cancer Patients. GEBURTSHILFE UND FRAUENHEILKUNDE, 81: 469-480 [33867564](#)

IF: 2,754; anteiliger IF: 0,051

39. Mitra D., Vega-Rubin-de-Celis S., Royla N., Bernhardt S., Wilhelm H., Tarade N., Poschet G., Buettner M., Binenbaum I., Borgoni S., Vetter M., Kantelhardt E.J., Thomssen C., Chatziioannou A., Hell R., Kempa S., Müller-Decker K., Wiemann S.: (2021) Abrogating GPT2 in triple-negative breast cancer inhibits tumor growth and promotes autophagy. INTERNATIONAL JOURNAL OF CANCER, 148: 1993-2009 [33368291](#)
IF: 7,316; anteiliger IF: 0,45725
40. Nees L.K., Grozinger P., Orthmann N., Rippinger N., Hennigs A., Sohn C., Domschke C., Wallwiener M., Rom J., Riedel F.: (2021) The Influence of Different Genres of Music on the Performance of Medical Students on Standardized Laparoscopic Exercises. Journal of Surgical Education, 78: 1709 [33812805](#)
IF: 3,524; anteiliger IF: 0,14695
41. Nees L.K., Grozinger P., Orthmann N., Deutsch T.M., Hennigs A., Domschke C., Wallwiener M., Rom J., Riedel F.: (2021) Evaluating the influence of music at different sound pressure levels on medical students' performance of standardized laparoscopic box training exercises. BMC Medical Education, 21: 209 [33849503](#)
IF: 3,263; anteiliger IF: 0,15532
42. Piccart M., Procter M., Fumagalli D., de Azambuja E., Clark E., Ewer M.S., Restuccia E., Jerusalem G., Dent S., Reaby L., Bonnefoi H., Krop I., Liu T.W., Pieńkowski T., Toi M., Wilcken N., Andersson M., Im Y.H., Tseng L.M., Lueck H.J., Colleoni M., Monturus E., Sicoe M., Guillaume S., Bines J., Gelber R.D., Viale G., Thomssen C., APHINITY Steering Committee and Investigators: (2021) Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. Journal of clinical oncology, 39: 1448-1457 [33539215](#)
IF: 50,717; anteiliger IF: 16,90398
43. Prieske K., Woelber L., Muallem M.Z., Eulenburg C., Jueckstock J.K., Hilpert F., de Gregorio N., Iborra S., Ignatov A., Hillemanns P., Fuerst S., Strauss H.G., Baumann K., Beckmann M., Mustea A., Meier W., Harter P., Wimberger P., Sehoul J., Mahner S.: (2021) Age, treatment and prognosis of patients with squamous cell vulvar cancer (VSCC) - analysis of the AGO-CaRE-1 study. GYNECOLOGIC ONCOLOGY, 161: 442-448 [33648748](#)
IF: 5,304; anteiliger IF: 0,09822
44. Ramachandran D., Wang Y., Schürmann P., Hülse F., Mao Q., Jentschke M., Böhmer G., Strauß H.G., Hirchenhain C., Schmidmayr M., Müller F., Runnebaum I., Hein A., Koch M., Ruebner M., Beckmann M.W., Fasching P.A., Luyten A., Dürst M., Hillemanns P., Dörk T.: (2021) Association of genomic variants at PAX8 and PBX2 with cervical cancer risk. INTERNATIONAL JOURNAL OF CANCER, 1: 1-10 [33905146](#)
IF: 7,316; anteiliger IF: 0,12835
45. Reibold C.F., Tariku W., Eber-Schulz P., Getachew S., Addisie A., Unverzagt S., Wienke A., Hauptmann S., Wickenhauser C., Vetter M., Jemal A., Thomssen C., Kantelhardt E.J.: (2021) Adherence to Newly Implemented Tamoxifen Therapy for Breast Cancer Patients in Rural Western Ethiopia. BREAST CARE, 16: 484 [34720808](#)
IF: 2,268; anteiliger IF: 1,71809
46. Riedel F., Hoffmann A.S., Moderow M., Feisst M., Heublein S., Deutsch T.M., Schäffgen B., Golatta M., Domschke C., Wallwiener M., Heil J., Hennigs A.: (2021) Do hospital type or caseload make a difference in chemotherapy treatment patterns for early breast cancer? Results from 104 German institutions, 2008-2017. BREAST, 58: 63 [33933924](#)
IF: 4,254; anteiliger IF: 0,14166
47. Seppälä T.T., Dominguez-Valentin M., Crosbie E.J., Engel C., Aretz S., Macrae F., Winship I., Capella G., Thomas H., Hovig E., Nielsen M., Sijmons R.H., Bertario L., Bonanni B., Tibiletti M.G., Cavestro G.M., Mints M., Gluck N., Katz L., Heinimann K., Vaccaro C.A., Green K., Laloo F., Hill J., Schmiegel W., Vangala D., Perne C., Strauß H.G., Tecklenburg J., Holinski-Feder E., Steinke-Lange V., Mecklin J.P., Plazzer J.P., Pineda M., Navarro M., Vida J.B., Kariv R., Rosner G., Piñero T.A., Pavicic W., Kalfayan P., Ten Broeke S.W., Jenkins M.A., Sunde L., Bernstein I., Burn J., Greenblatt M., de Vos Tot Nederveen Cappel W.H., Della Valle A., Lopez-Koestner F., Alvarez K., Büttner R., Görgens H., Morak M., Holzapfel S., Hüneburg R., von Knebel Doeberitz M., Loeffler M., Redler S., Weitz J., Pylvänäinen K., Renkonen-Sinisalo L., Lepistö A., Hopper J.L., Win A.K., Lindor N.M., Gallinger S., Le Marchand L., Newcomb P.A., Figueiredo J.C., Thibodeau S.N., Therkildsen C., Wadt K.A.W., Mourits M.J.E., Ketabi Z., Denton O.G., Rødland E.A., Vasen H., Neffa F., Esperon P., Tjandra D., Mösllein G., Rokkones E., Sampson J.R., Evans D.G., Møller P.: (2021) Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. EUROPEAN JOURNAL OF CANCER, 148: 124-133 [33743481](#)
IF: 10,002; anteiliger IF: 0,03969

48. Seraphin T.P., Joko-Fru W.Y., Hämmerl L., Griesel M., Mezger N.C.S., Feuchtner J.C., Adoubi I., Egué M.D.D., Okerosi N., Wabinga H., Hansen R., Vuma S., Lorenzoni C., Coulibaly B., Odzebe S.W., Buziba N.G., Aynalem A., Liu B., Medenwald D., Mikolajczyk R.T., Efstathiou J.A., Parkin D.M., Jemal A., Kantelhardt E.J.: (2021) Presentation, patterns of care, and outcomes of patients with prostate cancer in sub-Saharan Africa: A population-based registry study. *CANCER*, 127: 4221 [34328216](#)
IF: 6,921; anteiliger IF: 5,03457
49. Seraphin T.P., Joko-Fru W.Y., Kamaté B., Chokunonga E., Wabinga H., Somdyala N.I.M., Manraj S.S., Ogunbiyi O.J., Dzamalala C.P., Finesse A., Korir A., N'Da G., Lorenzoni C., Liu B., Kantelhardt E.J., Parkin D.M.: (2021) Rising Prostate Cancer Incidence in Sub-Saharan Africa: A Trend Analysis of Data from the African Cancer Registry Network. *CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION*, 30: 158-165 [33033143](#)
IF: 4,09; anteiliger IF: 1,46054
50. Seraphin T.P., Joko-Fru W.Y., Manraj S.S., Chokunonga E., Somdyala N.I.M., Korir A., N'Da G., Finesse A., Wabinga H., Assefa M., Gnanon F., Hansen R., Buziba N.G., Liu B., Kantelhardt E.J., Parkin D.M.: (2021) Prostate cancer survival in sub-Saharan Africa by age, stage at diagnosis, and human development index: a population-based registry study. *CANCER CAUSES & CONTROL*, 32: 1001-1019 [34244896](#)
IF: 2,532; anteiliger IF: 0,9042
51. Stickeler E., Aktas B., Behrens A., Belleville E., Ditsch N., Fasching P.A., Fehm T.N., Hartkopf A.D., Jackisch C., Janni W., Kolberg-Liedtke C., Kolberg H.C., Lüftner D., Lux M.P., Müller V., Schneeweiss A., Schütz F., Schulmeyer C.E., Tesch H., Thomssen C., Uleer C., Untch M., Welslau M., Wöckel A., Wurmthaler L.A., Würstlein R., Thill M.: (2021) Update Breast Cancer 2021 Part 1 - Prevention and Early Stages. *GEBURTSHILFE UND FRAUENHEILKUNDE*, 81: 526-538 [34035547](#)
IF: 2,754; anteiliger IF: 0,03672
52. Stolpner I., Heil J., Riedel F., Wallwiener M., Schäffgen B., Feißt M., Golatta M., Hennigs A.: (2021) Long-Term Patient Satisfaction and Quality of Life After Breast-Conserving Therapy: A Prospective Study Using the BREAST-Q. *ANNALS OF SURGICAL ONCOLOGY*, 28: 8742 [34279753](#)
IF: 4,339; anteiliger IF: 0,24125
53. Stoeter O., Seraphin T.P., Chitsike I., Chokunonga E., Kambugu J.B., Wabinga H., Parkin D.M., Kantelhardt E.J.: (2021) Trends in childhood cancer incidence in sub-Saharan Africa: Results from 25 years of cancer registration in Harare (Zimbabwe) and Kyadondo (Uganda). *INTERNATIONAL JOURNAL OF CANCER*, 149: 1002-1012 [33945631](#)
IF: 7,316; anteiliger IF: 5,28386
54. Teka B., Gizaw M., Ruddies F., Addissie A., Chanyalew Z., Skof A.S., Thies S., Mihret A., Kantelhardt E.J., Kaufmann A.M., Abebe T.: (2021) Population-based human papillomavirus infection and genotype distribution among women in rural areas of South Central Ethiopia. *INTERNATIONAL JOURNAL OF CANCER*, 148: 723-730 [32875552](#)
IF: 7,316; anteiliger IF: 0,81208
55. Tesfaw A., Getachew S., Addissie A., Jemal A., Wienke A., Taylor L., Kantelhardt E.J.: (2021) Late-Stage Diagnosis and Associated Factors Among Breast Cancer Patients in South and Southwest Ethiopia: A Multicenter Study. *Clinical Breast Cancer*, 21: e112-e119 [33536135](#)
IF: 3,078; anteiliger IF: 1,2313
56. Teshome B., Trabitzsch J., Afework T., Addissie A., Kaba M., Kantelhardt E.J., Getachew S.: (2021) Perceived barriers to timely treatment initiation and social support status among women with breast cancer in Ethiopia. *PLoS One*, 16: e0257163 [34516552](#)
IF: 3,752; anteiliger IF: 3,00147
57. Thill M., Friedrich M., Kolberg-Liedtke C., Albert U.S., Banys-Paluchowski M., Bauerfeind I., Blohmer J.U., Budach W., Dall P., Fallenberg E.M., Fasching P.A., Fehm T., Gerber B., Gluz O., Harbeck N., Heil J., Huober J., Jackisch C., Kreipe H.H., Krug D., Kühn T., Kümmel S., Loibl S., Lüftner D., Lux M.P., Maass N., Mundhenke C., Nitz U., Park-Simon T.W., Reimer T., Rhiem K., Rody A., Schmidt M., Schneeweiss A., Schütz F., Sinn H.P., Solbach C., Solomayer E.F., Stickeler E., Thomssen C., Untch M., Witzel I., Wöckel A., Müller V., Janni W., Ditsch N.: (2021) AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021. *BREAST CARE*, 16: 228-235 [34248463](#)
IF: 2,268; anteiliger IF: 0,01718
58. Thomssen C., Balic M., Harbeck N., Gnant M.: (2021) St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer. *BREAST CARE*, 16: 135-143 [34002112](#)
IF: 2,268; anteiliger IF: 0,756

59. Trojan A., Leuthold N., Thomssen C., Rody A., Winder T., Jakob A., Egger C., Held U., Jackisch C.: (2021) The Effect of Collaborative Reviews of Electronic Patient-Reported Outcomes on the Congruence of Patient- and Clinician-Reported Toxicity in Cancer Patients Receiving Systemic Therapy: Prospective, Multicenter, Observational Clinical Trial. JOURNAL OF MEDICAL INTERNET RESEARCH, 23: e29271 [34383675](#)
IF: 7,076; anteiliger IF: 0,33695
60. Untch M., Fasching P.A., Brucker S.Y., Budach W., Denkert C., Haidinger R., Huober J., Jackisch C., Janni W., Kolberg-Liedtke C., Krug D., Kühn T., Loibl S., Lüftner D., Müller V., Schneeweiss A., Thill M., Harbeck N., Thomssen C.: (2021) Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference. GEBURTSHILFE UND FRAUENHEILKUNDE, 81: 637-653 [34168378](#)
IF: 2,754; anteiliger IF: 0,918
61. Woelber L., Bommert M., Harter P., Prieske K., Zu Eulenburg C., Jueckstock J., Hilpert F., de Gregorio N., Iborra S., Sehouli J., Ignatov A., Hillemanns P., Fuerst S., Strauss H.G., Baumann K., Beckmann M., Mustea A., Meier W., Mahner S., Jaeger A.: (2021) Role of Pelvic Lymph Node Resection in Vulvar Squamous Cell Cancer: A Subset Analysis of the AGO-CaRE-1 Study. ANNALS OF SURGICAL ONCOLOGY, 28: 6696-6704 [33723714](#)
IF: 4,339; anteiliger IF: 0,08035
62. Woelber L., Prieske K., Eulenburg C., Oliveira-Ferrer L., de Gregorio N., Klapdor R., Kalder M., Braicu I., Fuerst S., Klar M., Strauss H.G., Beckmann M., Meier W., Ignatov A., Mustea A., Jueckstock J., Schmidt G., Bauerschlag D., Hellriegel M., Canzler U., Petry K.U., Kommos S., Hantschmann P., Heubner M., Mahner S., Burandt E.: (2021) p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft Gynäkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 224: 595.e1-595.e11 [33453182](#)
IF: 10,693; anteiliger IF: 0,14851
63. Woldetensay Y.K., Belachew T., Ghosh S., Kantelhardt E.J., Biesalski H.K., Scherbaum V.: (2021) The effect of maternal depressive symptoms on infant feeding practices in rural Ethiopia: community based birth cohort study. International Breastfeeding Journal, 16: 27 [33743775](#)
IF: 3,79; anteiliger IF: 0,31583

2021 Summe der Bewertungen: 72,53445, Summe IF = 427.07

Originalarbeit

1. Afework T., Wondimagegnehu A., Bogale A.S., Kantelhardt E.J., Addissie A.: (2022) Predictors of unmet supportive care needs of adult cancer patients in Ethiopia. EUROPEAN JOURNAL OF CANCER CARE, 31: e13694 [36065621](#)
IF: 2,1; anteiliger IF: 0,93333
2. Aktas B., Fehm T.N., Welslau M., Müller V., Lüftner D., Schütz F., Fasching P.A., Janni W., Thomssen C., Witzel I., Belleville E., Untch M., Thill M., Tesch H., Ditsch N., Lux M.P., Banys-Paluchowski M., Kolberg-Liedtke C., Hartkopf A.D., Wöckel A., Kolberg H.C., Stickeler E., Harbeck N., Schneeweiss A.: (2022) Update Breast Cancer 2022 Part 4 - Advanced-Stage Breast Cancer. GEBURTSHILFE UND FRAUENHEILKUNDE, 82: 922-931 [36110891](#)
IF: 2,7; anteiliger IF: 0,04091
3. Ayele W., Führer A., Braun G.A., Formazin F., Wienke A., Taylor L., Unverzagt S., Addissie A., Kantelhardt E.J.: (2022) Breast cancer morbidity and mortality in rural Ethiopia: data from 788 verbal autopsies. BMC WOMENS HEALTH, 22: 89 [35331210](#)
IF: 2,5; anteiliger IF: 2,02381
4. Bachmann H.S., Jung D., Link T., Arnold A., Kantelhardt E., Thomssen C., Wimberger P., Vetter M., Kuhlmann J.D.: (2022) FNTB Promoter Polymorphisms Are Independent Predictors of Survival in Patients with Triple Negative Breast Cancer. Cancers, 14: 468 [35158735](#)
IF: 5,2; anteiliger IF: 2,2284
5. Banys-Paluchowski M., Thill M., Kühn T., Ditsch N., Heil J., Wöckel A., Fallenberg E., Friedrich M., Kümmel S., Müller V., Janni W., Albert U.S., Bauerfeind I., Blohmer J.U., Budach W., Dall P., Fasching P., Fehm T., Gluz O., Harbeck N., Huober J., Jackisch C., Kolberg-Liedtke C., Kreipe H.H., Krug D., Loibl S., Lüftner D., Lux M.P., Maass N., Mundhenke C., Nitz U., Park-Simon T.W., Reimer T., Rhiem K., Rody A., Schmidt M., Schneeweiss

- A., Schütz F., Sinn H.P., Solbach C., Solomayer E.F., Stickeler E., Thomssen C., Untch M., Witzel I., Gerber B.: (2022) AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022. GEBURTSHILFE UND FRAUENHEILKUNDE, 82: 1031-1043 [36186147](#)
IF: 2,7; anteiliger IF: 0,02045
6. Burandt E., Blessin N.C., Rolschewski A.C., Lutz F., Mandelkow T., Yang C., Bady E., Reiswich V., Simon R., Sauter G., Mahner S., Gregorio N.d., Klapdor R., Kalder M., Braicu E.I., Fürst S., Klar M., Strauß H.G., Prieske K., Wölber L.: (2022) T-Cell Density at the Invasive Margin and Immune Phenotypes Predict Outcome in Vulvar Squamous Cell Cancer. Cancers, 14: 4246. [36077784](#)
IF: 5,2; anteiliger IF: 0,0963
7. Cernota M., Kroeber E.S., Demeke T., Frese T., Getachew S., Kantelhardt E.J., Ngeh E.N., Unverzagt S.: (2022) Non-pharmacological interventions to achieve blood pressure control in African patients: a systematic review. BMJ OPEN, 12: e048079 [35228272](#)
IF: 2,9; anteiliger IF: 0,16111
8. COVIDSurg Collaborative, GlobalSurg Collaborative, Kissner U., Kleeff J., Klose J., Lorenz K., Papendick N., Plontke S., Ronellenfisch U., Seiwert H., Steer S., Thomssen C., Ukkat J., Scherl C.: (2022) SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study. ANAESTHESIA, 77: 28-39 [34428858](#)
IF: 10,7; anteiliger IF: 0,29936
9. Czapiewski P., Cornelius M., Hartig R., Kalinski T., Haybaeck J., Dittmer A., Dittmer J., Ignatov A., Nass N.: (2022) BCL3 expression is strongly associated with the occurrence of breast cancer relapse under tamoxifen treatment in a retrospective cohort study. VIRCHOWS ARCHIV, 480: 529-541 [35020071](#)
IF: 3,5; anteiliger IF: 0,33333
10. Demeke T., Ayele W., Haile Mariam D., Wienke A., Assefa M., Addissie A., Mikolajczyk R., Unverzagt S., Kantelhardt E.J.: (2022) Health system cost of breast cancer treatment in Addis Ababa, Ethiopia. PLoS One, 17: e0275171 [36201488](#)
IF: 3,7; anteiliger IF: 2,29044
11. Denschlag D., Ackermann S., Battista M.J., Cremer W., Egerer G., Fehr M., Follmann M., Haase H., Harter P., Hettmer S., Horn L.C., Juhasz-Boess I., Kast K., Köhler G., Kröncke T., Lindel K., Mallmann P., Meyer-Steinacker R., Mustea A., Petru E., Reichardt P., Schmidt D., Strauss H.G., Thiel F., Ulrich U.A., Vogl T., Vordermark D., Wallwiener M., Gass P., Beckmann M.W.: (2022) Sarcoma of the Uterus. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/074, April 2021). GEBURTSHILFE UND FRAUENHEILKUNDE, 82: 1337-1367 [36467974](#)
IF: 2,7; anteiliger IF: 0,06427
12. Desalegn Z., Sebre S., Yohannes M., Seman A., Shiferaw W., Ademe M., Biazin H., Firdawoke E., Asemamaw Y., Teka B., Teshome S., Amogne W., Addissie A., Gebrehiwot Y., Kantelhardt E., Abebe T.: (2022) Comparison of the Diagnostic Performance of a Rapid Antigen Test with Real-Time Polymerase Chain Reaction for Detection of SARS-CoV-2 Among Patients Diagnosed with COVID-19 at Selected Hospitals in Addis Ababa, Ethiopia. Infection and Drug Resistance, 15: 4299-4305 [35965848](#)
IF: 3,9; anteiliger IF: 0,18571
13. Desalegn Z., Yohannes M., Porsch M., Stückrath K., Anberber E., Santos P., Bauer M., Addissie A., Bekuretsion Y., Assefa M., Worku Y., Taylor L., Abebe T., Kantelhardt E.J., Vetter M.: (2022) Intrinsic subtypes in Ethiopian breast cancer patient. BREAST CANCER RESEARCH AND TREATMENT, 196: 495-504 [36282363](#)
IF: 3,8; anteiliger IF: 2,7282
14. De Wilde R.L., Devassy R., Broek R., Miller C.E., Adlan A., Aquino P., Becker S., Darmawan F., Gergolet M., Habana M.A.E., Khoo C.K., Koninckx P.R., Korell M., Krentel H., Musigavong O., Pistofidis G., Puntambekar S., Rachman I.A., Sendag F., Wallwiener M., Torres-de la Roche L.A.: (2022) The Future of Adhesion Prophylaxis Trials in Abdominal Surgery: An Expert Global Consensus. Journal of Clinical Medicine, 11: 1476 [35329802](#)
IF: 3,9; anteiliger IF: 0,06825
15. Ditsch N., Wöcke A., Untch M., Jackisch C., Albert U.S., Banys-Paluchowski M., Bauerfeind I., Blohmer J.U., Budach W., Dall P., Fallenberg E.M., Fasching P.A., Fehm T.N., Friedrich M., Gerber B., Gluz O., Harbeck N., Heil J., Huober J., Kreipe H.H., Krug D., Kühn T., Kümmel S., Kolberg-Liedtke C., Loibl S., Lüftner D., Lux M.P., Maass N., Mundhenke C., Nitz U., Park-Simon T.W., Reimer T., Rhiem K., Rody A., Schmidt M., Schneeweiss A., Schütz F., Sinn H.P., Solbach C., Solomayer E.F., Stickeler E., Thomssen C., Witzel I., Müller V., Janni W., Thill M.: (2022) AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022. BREAST CARE, 17: 403-420 [36156915](#)

IF: 2,1; anteiliger IF: 0,01591

16. Dittmer A., Dittmer J.: (2022) A CAF-Fueled TIMP-1/CD63/ITGB1/STAT3 Feedback Loop Promotes Migration and Growth of Breast Cancer Cells. *Cancers*, 14: 4983 [36291767](#)
IF: 5,2; anteiliger IF: 5,2
17. Dittmer J.: (2022) Biological effects and regulation of IGFBP5 in breast cancer. *Frontiers in Endocrinology*, 13: 983793 [36093095](#)
IF: 5,2; anteiliger IF: 5,2
18. Engler T., Fasching P.A., Lüftner D., Hartkopf A.D., Müller V., Kolberg H.C., Hadji P., Tesch H., Häberle L., Ettl J., Wallwiener M., Beckmann M.W., Hein A., Belleville E., Uhrig S., Wimberger P., Hielscher C., Kurbacher C.M., Wuerstlein R., Untch M., Taran F.A., Enzinger H.M., Krabisch P., Welslau M., Maasberg M., Hempel D., Lux M.P., Michel L.L., Janni W., Wallwiener D., Brucker S.Y., Fehm T.N., Schneeweiss A.: (2022) Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANT. *GEBURTSHILFE UND FRAUENHEILKUNDE*, 82: 1055 [36186151](#)
IF: 2,7; anteiliger IF: 0,02916
19. Erber R., Angeloni M., Stöhr R., Lux M.P., Ulbrich-Gebauer D., Pelz E., Bankfalvi A., Schmid K.W., Walter R.F.H., Vetter M., Thomssen C., Mayr D., Klauschen F., Sinn P., Sotlar K., Stering K., Stenzinger A., Wunderle M., Fasching P.A., Beckmann M.W., Hoffmann O., Kimmig R., Harbeck N., Wuerstlein R., Ferrazzi F., Hartmann A.: (2022) Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World Setting. *INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES*, 23: 8716 [35955851](#)
IF: 5,6; anteiliger IF: 0,15556
20. Fehm T.N., Welslau M., Müller V., Lüftner D., Schütz F., Fasching P.A., Janni W., Thomssen C., Witzel I., Belleville E., Untch M., Thill M., Tesch H., Ditsch N., Lux M.P., Aktas B., Banys-Paluchowski M., Schneeweiss A., Kolberg-Liedtke C., Hartkopf A.D., Wöckel A., Kolberg H.C., Harbeck N., Stickeler E.: (2022) Update Breast Cancer 2022 Part 3 - Early-Stage Breast Cancer. *GEBURTSHILFE UND FRAUENHEILKUNDE*, 82: 912-921 [36110894](#)
IF: 2,7; anteiliger IF: 0,04091
21. Fekadu A., Rick T.J., Tigeneh W., Kantelhardt E.J., Incrocci L., Jemal A.: (2022) Clinicopathology and Treatment Patterns of Head and Neck Cancers in Ethiopia. *JCO Global Oncology*, 8: e2200073 [35939776](#)
IF: 4,5; anteiliger IF: 0,375
22. Fischer C., Deutsch T.M., Feisst M., Rippinger N., Riedel F., Hartkopf A.D., Brucker S.Y., Domschke C., Fremd C., Michel L., Burwinkel B., Schneeweiss A., Turchinovich A., Wallwiener M.: (2022) Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer. *ARCHIVES OF GYNECOLOGY AND OBSTETRICS*, 306: 875 [35237856](#)
IF: 2,6; anteiliger IF: 0,86658
23. Fischer C., Turchinovich A., Feisst M., Riedel F., Haßdenteufel K., Scharli P., Hartkopf A.D., Brucker S.Y., Michel L., Burwinkel B., Schneeweiss A., Wallwiener M., Deutsch T.M.: (2022) Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment. *INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES*, 23: 9535 [36076930](#)
IF: 5,6; anteiliger IF: 0,16968
24. Foerster M., McCormack V., Anderson B.O., Boucheron P., Zietsman A., Cubasch H., Joffe M., Anele A., Offiah S., Galukande M., Parham G., Pinder L.F., Ginsburg O., Schüz J., Dos-Santos-Silva I., Kantelhardt E.J.: (2022) Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer-Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa: a prospective cohort study. *LANCET ONCOLOGY*, 23: 729-738 [35550274](#)
IF: 51,1; anteiliger IF: 17,03333
25. Getachew S., Addissie A., Seife E., Wakuma T., Unverzagt S., Jemal A., Taylor L., Wienke A., Kantelhardt E.J.: (2022) Breast Nurse Intervention to Improve Adherence to Endocrine Therapy Among Breast Cancer Patients in South Ethiopia. *ONCOLOGIST*, 27: e650 [35524760](#)
IF: 5,8; anteiliger IF: 4,14286
26. Getu M.A., Chen C., Addissie A., Seife E., Wang P., Kantelhardt E.J.: (2022) A pilot study of cognitive behavioural therapy integrated with activity pacing for fatigued breast cancer patients undergoing chemotherapy in Ethiopia. *Frontiers in Oncology*, 12: 847400 [36212410](#)

IF: 4,7; anteiliger IF: 3,525

27. Getu M.A., Chen C., Wang P., Kantelhardt E.J., Addissie A.: (2022) Quality of life and its influencing factors among breast cancer patients at Tikur Anbessa specialised hospital, Addis Ababa, Ethiopia. BMC CANCER, 22: 897 [35978281](#)
IF: 3,8; anteiliger IF: 2,95556
28. Getu M.A., Wang P., Kantelhardt E.J., Seife E., Chen C., Addissie A.: (2022) Translation and validation of the EORTC QLQ-BR45 among Ethiopian breast cancer patients. Scientific Reports, 12: 605 [35906247](#)
IF: 4,6; anteiliger IF: 1,91667
29. Gizaw M., Parkin D.M., Stöter O., Korir A., Kamate B., Liu B., Bojang L., N'Da G., Manraj S.S., Bukirwa P., Chokunonga E., Chingonzoh T., Peko J.F., Finesse A., Somdyala N., Ladipo A., Kantelhardt E.J.: (2022) Trends in the incidence of ovarian cancer in sub-Saharan Africa. INTERNATIONAL JOURNAL OF CANCER, Epub: Epub [36274630](#)
IF: 6,4; anteiliger IF: 4,40853
30. Graf J., Sickenberger N., Brusniak K., Matthies L.M., Deutsch T.M., Simoes E., Plappert C., Keilmann L., Hartkopf A., Walter C.B., Hahn M., Engler T., Wallwiener S., Schuetz F., Fasching P.A., Schneeweiss A., Brucker S.Y., Wallwiener M.: (2022) Implementation of an Electronic Patient-Reported Outcome App for Health-Related Quality of Life in Breast Cancer Patients: Evaluation and Acceptability Analysis in a Two-Center Prospective Trial. JOURNAL OF MEDICAL INTERNET RESEARCH, 24: e16128 [35133288](#)
IF: 7,4; anteiliger IF: 2,46642
31. Heil J., Pfof A., Sinn H.P., Rauch G., Bach P., Thomas B., Schaeffgen B., Kuemmel S., Reimer T., Hahn M., Thill M., Blohmer J.U., Hackmann J., Malter W., Bekes I., Friedrichs K., Wojcinski S., Joos S., Paepke S., Ditsch N., Rody A., Große R., van Mackelenbergh M., Reinisch M., Karsten M., Golatta M., RESPONDER Investigators: (2022) Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03. ANNALS OF SURGERY, 275: 576-581 [32657944](#)
IF: 9; anteiliger IF: 0,12
32. Kolberg-Liedtke C., Lüftner D., Brucker S.Y., Budach W., Denkert C., Fasching P.A., Haidinger R., Harbeck N., Huober J., Jackisch C., Janni W., Krug D., Kühn T., Loibl S., Müller V., Schneeweiss A., Thomssen C., Untch M., Thill M.: (2022) Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference. BREAST CARE, 17: 336-345 [35957945](#)
IF: 2,1; anteiliger IF: 0,04118
33. Lüftner D., Fasching P.A., Haidinger R., Harbeck N., Jackisch C., Müller V., Schumacher-Wulf E., Thomssen C., Untch M., Würstlein R.: (2022) ABC6 Consensus: Assessment by a Group of German Experts. BREAST CARE, 17: 90-100 [35355695](#)
IF: 2,1; anteiliger IF: 0,0875
34. Lüftner D., Schütz F., Stickeler E., Fasching P.A., Janni W., Kolberg-Liedtke C., Kolberg H.C., Thomssen C., Müller V., Fehm T.N., Belleville E., Bader S., Untch M., Welslau M., Thill M., Tesch H., Ditsch N., Lux M.P., Wöckel A., Aktas B., Schneeweiss A., Würstlein R., Hartkopf A.D.: (2022) Update Breast Cancer 2021 Part 5 - Advanced Breast Cancer. GEBURTSHILFE UND FRAUENHEILKUNDE, 82: 215-225 [35169389](#)
IF: 2,7; anteiliger IF: 0,04286
35. Meixner E., Sandrini E., Hoeltgen L., Eichkorn T., Hoegen P., König L., Arians N., Lischalk J.W., Wallwiener M., Weis I., Roob D., Debus J., Hörner-Rieber J.: (2022) Return to Work, Fatigue and Cancer Rehabilitation after Curative Radiotherapy and Radiochemotherapy for Pelvic Gynecologic Cancer. Cancers, 14: 2330 [35565459](#)
IF: 5,2; anteiliger IF: 0,15756
36. Midaksa M., Destaw A., Addissie A., Kantelhardt E.J., Gizaw M.: (2022) Women's sexual autonomy as a determinant of cervical cancer screening uptake in Addis Ababa, Ethiopia: a case-control study. BMC WOMENS HEALTH, 22: 236 [35715797](#)
IF: 2,5; anteiliger IF: 1,11111
37. Müller V., Hein A., Hartkopf A.D., Fasching P.A., Kolberg H.C., Hadji P., Tesch H., Häberle L., Ettl J., Lüftner D., Wallwiener M., Beckmann M.W., Schneeweiss A., Belleville E., Uhrig S., Wimberger P., Hielscher C., Meyer J., Wurmthaler L.A., Kurbacher C.M., Wuerstlein R., Untch M., Janni W., Taran F.A., Lux M.P., Wallwiener D., Brucker S.Y., Fehm T.N., Michel L.L.: (2022) Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry.

EUROPEAN JOURNAL OF CANCER, 172: 13 [35728342](#)

IF: 8,4; anteiliger IF: 0,10332

38. Müller V., Welslau M., Lüftner D., Schütz F., Stickeler E., Fasching P.A., Janni W., Thomssen C., Witzel I., Fehm T.N., Belleville E., Bader S., Seitz K., Untch M., Thill M., Tesch H., Ditsch N., Lux M.P., Aktas B., Banys-Paluchowski M., Schneeweiss A., Harbeck N., Würstlein R., Hartkopf A.D., Kolberg H.C., Wöckel A.: (2022) Update Breast Cancer 2022 Part 2 - Advanced Stage Breast Cancer. GEBURTSHILFE UND FRAUENHEILKUNDE, 82: 590-600 [35903715](#)
IF: 2,7; anteiliger IF: 0,0375
39. Nees J., Schafferer S., Yuan B., Tang Q., Scheffler M., Hartkopf A., Golatta M., Schneeweiß A., Burwinkel B., Wallwiener M.: (2022) How previous treatment changes the metabolomic profile in patients with metastatic breast cancer. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 306: 2115 [35467121](#)
IF: 2,6; anteiliger IF: 0,86658
40. Nees L.K., Heublein S., Steinmacher S., Juhasz-Böss I., Brucker S., Tempfer C.B., Wallwiener M.: (2022) Endometrial hyperplasia as a risk factor of endometrial cancer. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 306: 407 [35001185](#)
IF: 2,6; anteiliger IF: 0,86658
41. Pfof A., Sidey-Gibbons C., Rauch G., Thomas B., Schaeffgen B., Kuemmel S., Reimer T., Hahn M., Thill M., Blohmer J.U., Hackmann J., Malter W., Bekes I., Friedrichs K., Wojcinski S., Joos S., Paepke S., Degenhardt T., Rom J., Rody A., van Mackelenbergh M., Banys-Paluchowski M., Große R., Reinisch M., Karsten M., Golatta M., Heil J.: (2022) Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery. Journal of clinical oncology, 40: 1903-1915 [35108029](#)
IF: 45,3; anteiliger IF: 0,604
42. Pixberg C., Zapatka M., Hlevnjak M., Benedetto S., Suppelna J.P., Heil J., Smetanay K., Michel L., Fremd C., Körber V., Rübsam M., Buschhorn L., Heublein S., Schäffgen B., Golatta M., Gomez C., von Au A., Wallwiener M., Wolf S., Dikow N., Schaaf C., Gutjahr E., Allgäuer M., Stenzinger A., Pfütze K., Kirsten R., Hübschmann D., Sinn H.P., Jäger D., Trumpp A., Schlenk R., Höfer T., Thewes V., Schneeweiss A., Lichter P.: (2022) COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy. ESMO Open, 7: 100637 [36423362](#)
IF: 7,3; anteiliger IF: 0,07373
43. Ramachandran D., Dennis J., Fachal L., Schürmann P., Bousset K., Hülse F., Mao Q., Wang Y., Jentschke M., Böhmer G., Strauß H.G., Hirchenhain C., Schmidmayr M., Müller F., Runnebaum I., Hein A., Stübs F., Koch M., Ruebner M., Beckmann M.W., Fasching P.A., Luyten A., Dürst M., Hillemanns P., Easton D.F., Dörk T.: (2022) Genome-wide association study and functional follow-up identify 14q12 as a candidate risk locus for cervical cancer. HUMAN MOLECULAR GENETICS, 31: 2483-2497 [35157032](#)
IF: 3,5; anteiliger IF: 0,04861
44. Reinhardt K., Stückrath K., Hartung C., Kaufhold S., Uleer C., Hanf V., Lantsch T., Peschel S., John J., Pöhler M., Bauer M., Bürrig F.K., Weigert E., Buchmann J., Kantelhardt E.J., Thomssen C., Vetter M.: (2022) PIK3CA-mutations in breast cancer. BREAST CANCER RESEARCH AND TREATMENT, 196: 483-493 [36279023](#)
IF: 3,8; anteiliger IF: 2,95556
45. Sandholzer-Yilmaz A.S., Kroeber E.S., Ayele W., Frese T., Kantelhardt E.J., Unverzagt S.: (2022) Randomised controlled trials on prevention, diagnosis and treatment of diabetes in African countries: a systematic review. BMJ OPEN, 12: e050021 [35545395](#)
IF: 2,9; anteiliger IF: 0,24167
46. Scholz A.S., Hassdenteufel K., Gutsfeld R., Müller M., Goetz M., Bauer A., Wallwiener M., Brucker S.Y., Joos S., Colombo M.G., Hawighorst-Knapstein S., Chaudhuri A., Beck F., Wallwiener S.: (2022) Observational database study on preeclampsia and postpartum medical care up to 7.5 years after birth. Scientific Reports, 12: 21230 [36482054](#)
IF: 4,6; anteiliger IF: 0,12788
47. Schüler K., Bethmann D., Kaufhold S., Hartung C., Stückrath K., Lantsch T., Uleer C., Hanf V., Peschel S., John J., Pöhler M., Buchmann J., Bürrig K.F., Weigert E., Thomssen C., Kantelhardt E.J., Vetter M.: (2022) Prognostic Value of Tumour-Infiltrating Lymphocytes in an Unselected Cohort of Breast Cancer Patients. Diagnostics, 12: 2527 [36292215](#)
IF: 3,6; anteiliger IF: 2,8
48. Teka B., Gizaw M., Firdawoke E., Addissie A., Sisay T.A., Schreckenberger C., Skof A.S., Thies S., Mihret A.,

Kantelhardt E.J., Abebe T., Kaufmann A.M.: (2022) A Technical Comparison of Human Papillomavirus Genotyping Assays from a Population-Based Cervical Cancer Screening in South Central Ethiopia. *Cancer Management and Research*, 14: 2253-2263 [35937937](#)

IF: 3,3; anteiliger IF: 1,32

49. Thill M., Lüftner D., Kolberg-Liedtke C., Albert U.S., Banyas-Paluchowski M., Bauerfeind I., Blohmer J.U., Budach W., Dall P., Fallenberg E.M., Fasching P.A., Fehm T., Friedrich M., Gerber B., Gluz O., Harbeck N., Heil J., Huober J., Jackisch C., Kreipe H.H., Krug D., Kühn T., Kümmel S., Loibl S., Lux M., Maass N., Mundhenke C., Nitz U., Park-Simon T.W., Reimer T., Rhiem K., Rody A., Schmidt M., Schneeweiss A., Schütz F., Sinn H.P., Solbach C., Solomayer E.F., Stickeler E., Thomssen C., Untch M., Witzel I., Wöckel A., Müller V., Janni W., Ditsch N.: (2022) AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022. *BREAST CARE*, 17: 421-429 [36156913](#)
IF: 2,1; anteiliger IF: 0,01591
50. Thomssen C.: (2022) [Management of immune-related adverse events (irAEs) - what needs to be respected?]. *Gynakologie*, 55: 344-350 [35494537](#)
IF: 0,2; anteiliger IF: 0,2
51. Thomssen C., Fehm T.N., Stickeler E., Fasching P.A., Janni W., Kolberg-Liedtke C., Kolberg H.C., Lüftner D., Müller V., Schütz F., Belleville E., Bader S., Untch M., Welslau M., Thill M., Hartkopf A.D., Tesch H., Ditsch N., Lux M.P., Wöckel A., Aktas B., Schneeweiss A., Würstlein R.: (2022) Update Breast Cancer 2021 Part 4 - Prevention and Early Stages. *GEBURTSHILFE UND FRAUENHEILKUNDE*, 82: 206-214 [35169388](#)
IF: 2,7; anteiliger IF: 0,9
52. Tietz S., Bodenbeck L., Riedel F., Wallwiener M., Hennigs A., Heublein S.: (2022) How to make students satisfied with digital teaching? Investigative results from teaching evaluations in Gynecology and Obstetrics. *ARCHIVES OF GYNECOLOGY AND OBSTETRICS*, 306: 1587 [35852646](#)
IF: 2,6; anteiliger IF: 0,21658
53. Torres-de la Roche L.A., Bérard V., de Wilde M.S., Devassy R., Wallwiener M., De Wilde R.L.: (2022) Chemically Modified Hyaluronic Acid for Prevention of Post-Surgical Adhesions: New Aspects of Gel Barriers Physical Profiles. *Journal of Clinical Medicine*, 11: 931 [35207204](#)
IF: 3,9; anteiliger IF: 0,32487
54. Trinh T.G., Schwarze C.E., Müller M., Goetz M., Hassdenteufel K., Wallwiener M., Wallwiener S.: (2022) Implementing a Perinatal Depression Screening in Clinical Routine: Exploring the Patient's Perspective. *GEBURTSHILFE UND FRAUENHEILKUNDE*, 82: 1082 [36186149](#)
IF: 2,7; anteiliger IF: 0,18009
55. Untch M., Fasching P.A., Haidinger R., Harbeck N., Jackisch C., Lüftner D., Müller V., Schumacher-Wulf E., Würstlein R., Thomssen C.: (2022) Advanced Breast Cancer: AGO Recommendations 2022 - Focus on ABC6 Consensus. *GEBURTSHILFE UND FRAUENHEILKUNDE*, 82: 1044-1054 [36186150](#)
IF: 2,7; anteiliger IF: 0,9
56. Volmer L., Koch A., Matovina S., Dannehl D., Weiss M., Welker G., Hahn M., Engler T., Wallwiener M., Walter C.B., Oberlechner E., Brucker S.Y., Pantel K., Hartkopf A.: (2022) Neoadjuvant Chemotherapy of Patients with Early Breast Cancer Is Associated with Increased Detection of Disseminated Tumor Cells in the Bone Marrow. *Cancers*, 14: 635 [35158902](#)
IF: 5,2; anteiliger IF: 0,14456
57. von Au A., Shencoru S., Uhlmann L., Mayer L., Michel L., Wallwiener M., Hennigs A., Deutsch T., Riedel F., Heil J., Golatta M., Schneeweiss A., Schütz F., Domschke C.: (2022) Predictive value of neutrophil-to-lymphocyte-ratio in neoadjuvant-treated patients with breast cancer. *ARCHIVES OF GYNECOLOGY AND OBSTETRICS*, Epub: Epub [35980458](#)
IF: 2,6; anteiliger IF: 0,07228
58. Von Au A., Wallwiener S., Matthies L.M., Friedrich B., Keim S., Wallwiener M., Reisenauer C., Brugger S.: (2022) The burden of incontinence in a real-world data environment-insights from a digital patient companion. *INTERNATIONAL UROGYNECOLOGY JOURNAL*, 33: 977 [33704535](#)
IF: 1,8; anteiliger IF: 0,10008
59. Welslau M., Müller V., Lüftner D., Schütz F., Stickeler E., Fasching P.A., Janni W., Thomssen C., Witzel I., Fehm T.N., Belleville E., Bader S., Seitz K., Untch M., Thill M., Tesch H., Ditsch N., Lux M.P., Aktas B., Banyas-Paluchowski M., Schneeweiss A., Harbeck N., Würstlein R., Hartkopf A.D., Wöckel A., Seliger B., Massa C., Kolberg H.C.: (2022) Update Breast Cancer 2022 Part 1 - Early Stage Breast Cancer. *GEBURTSHILFE UND FRAUENHEILKUNDE*, 82: 580-589 [35903719](#)

IF: 2,7; anteiliger IF: 0,03462

60. Woelber L., Prieske K., Eulenburg C.Z., Corradini S., Petersen C., Bommert M., Blankenstein T., Hilpert F., de Gregorio N., Iborra S., Sehouli J., Ignatov A., Hillemanns P., Fuerst S., Strauss H.G., Baumann K., Beckmann M.W., Mustea A., Mahner S., Jaeger A.: (2022) Adjuvant radiotherapy and local recurrence in vulvar cancer - a subset analysis of the AGO-CaRE-1 study. GYNECOLOGIC ONCOLOGY, 164: 68-75 [34794839](#)
IF: 4,7; anteiliger IF: 0,08704
61. Wondimagegnehu A., Negash Bereded F., Assefa M., Teferra S., Zebrack B., Addissie A., Kantelhardt E.J.: (2022) Burden of Cancer and Utilization of Local Surgical Treatment Services in Rural Hospitals of Ethiopia: A Retrospective Assessment from 2014 to 2019. ONCOLOGIST, 27: e889-e898 [35791963](#)
IF: 5,8; anteiliger IF: 4,25333
62. Zacher M., Wollanka N., Sauer C., Haßtentuefel K., Wallwiener S., Wallwiener M., Maatouk I.: (2022) Prenatal paternal depression, anxiety, and somatic symptom burden in different risk samples: an explorative study. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, Epub: Epub [35608702](#)
IF: 2,6; anteiliger IF: 0,17342

2022 Summe der Bewertungen: 79,18345, Summe IF = 332.0**Comment/Letter**

1. Harbeck N., Thomssen C., Gnant M.: (2020) Virtual Science in Senology: Let Us Not Throw out the Baby with the Bathwater. BREAST CARE, 15: 323-324 [32982640](#)
IF: 2,86; anteiliger IF: 0,09533

2020 Summe der Bewertungen: 0,09533, Summe IF = 2.86